Resolvin D1 (RvD1) and D2 (RvD2) are lipid mediators that are derived from docosahexaenoic acid. We recently demonstrated that intracerebroventricular (i.c.v.) infusions of RvD1 or RvD2 attenuate lipopolysaccharide-induced depression-like behaviors via mammalian target of rapamycin complex 1 signaling. However, the antidepressant effects of RvD1 and RvD2 have not been fully investigated. Here, we examined the antidepressant effects of RvD1 and RvD2 using the tail suspension test (TST) and forced swim test (FST) in murine chronic unpredictable stress (CUS) model. Male BALB/c mice (7 weeks) were subjected to 5 weeks of CUS and then received with a single i.c.v. infusion of RvD1 (10ng), RvD2 (10ng), or vehicle. In vehicle-infused mice, CUS significantly increased immobility in the TST both 2 and 24h after i.c.v. infusion, these depression-like behaviors were significantly ameliorated by RvD1 or RvD2. Similar results were obtained from the FST. Intracerebroventricular infusion of RvD1 or RvD2 did not affect locomotor activity. These results demonstrate that RvD1 and RvD2 produce rapid and sustained antidepressant effects in the CUS model.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbr.2017.06.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of plasma resolvin levels in women with breast cancer and their associations with disease presentation and immunohistochemical characteristics.
Lipids Health Dis
November 2024
Department of Surgical Sciences, Sapienza University of Rome, Rome, Italy.
Background: Resolvins, which are divided into series D (RvD) and E (RvE), originate from omega-3 fatty acids, DHA and EPA and were recently found to be involved in the modulation of inflammation in some tumors, including breast cancer (BC). We aimed to assess the resolvin profiles (RvD1, RvD2, RvD3 and RvE1) in the plasma of BC patients compared with those of controls and to determine differences in their concentrations according to BC presentation and immunohistochemical characteristics.
Methods: We considered BC patients (sporadic, familiar and BRCA1/2-mutated forms) naïve to any anticancer treatment and controls affected by nonmalignant breast disease.
Impact of Specialized Pro-Resolving Lipid Mediators on Craniofacial and Alveolar Bone Regeneration: Scoping Review.
Braz Dent J
October 2024
Dental Research Division, Guarulhos University, Guarulhos, SP, Brazil.
Article Synopsis
- - Craniofacial and alveolar bone defects from various causes (like tumors, trauma, or tooth loss) present significant challenges in tissue engineering and dental surgery, especially in cases of periodontal disease.
- - Specialized pro-resolving lipid mediators (SPMs) like lipoxins, resolvins, protectins, and maresins are being researched for their potential to enhance bone regeneration and restore tissue healing in craniofacial applications.
- - A total of 19 pre-clinical studies examined the effects of SPMs on bone regeneration, showing that SPMs notably increased new bone formation by about 14.85% and reduced defect size, with RvE1 and RvD2 demonstrating
Cardiac structural and functional changes in OSAHS patients with heart failure with preserved ejection fraction and atrial fibrillation.
BMC Cardiovasc Disord
October 2024
Department of Electrocardiogram Diagnosis, Wuming Hospital of Guangxi Medical University, Nanning, 530199, Guangxi Province, China.
Objective: To explore the cardiac structural and functional changes in obstructive sleep apnea-hypopnea syndrome (OSAHS) patients with heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF).
Methods: This retrospective study included 336 OSAHS patients with HFpEF. They were divided into Groups A (without an AF history and no AF episodes during cardiac color ultrasound examination), B (an AF history but no AF episodes), and C (an AF history and AF episodes).
Structural basis for the access and binding of resolvin D1 (RvD1) to formyl peptide receptor 2 (FPR2/ALX), a class A GPCR.
bioRxiv
September 2024
Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99224.
Article Synopsis
- Inflammation is crucial for defending against injuries and infections, but if it becomes uncontrolled, it can lead to chronic diseases like asthma, cancer, obesity, and diabetes.
- Specialized pro-resolving lipid mediators (SPMs), like resolvins (RvD1 and RvD2), help resolve inflammation and restore the body's balance, but a lack of SPMs can hinder this process.
- This study uses molecular simulations to explore how RvD1 interacts with its target receptor FPR2 from both aqueous and membrane environments, which could inform the development of new treatments for inflammatory diseases.
Low-dose pro-resolving mediators temporally reset the resolution response to microbial inflammation.
Mol Med
September 2024
Department of Anesthesiology, Perioperative and Pain Medicine, Center for Experimental Therapeutics and Reperfusion Injury, Mass General Brigham and Harvard Medical School, 60 Fenwood Rd., Hale Building for Transformative Medicine 3-016, Boston, MA, 02115, USA.
Background: Specialized pro-resolving mediators (SPMs) promote resolution of inflammation, clear infections and stimulate tissue regeneration. These include resolvins, protectins, and maresins. During self-resolving acute inflammation, SPMs are produced and have key functions activating endogenous resolution response for returning to homeostasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!